Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Synthetic Human Secretin in Children With Autism

This study has been completed.
Sponsor:
Information provided by:
Repligen Corporation
ClinicalTrials.gov Identifier:
NCT00036244
First received: May 8, 2002
Last updated: August 4, 2005
Last verified: August 2005

May 8, 2002
August 4, 2005
April 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00036244 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Synthetic Human Secretin in Children With Autism
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism

The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Autism
Drug: RG1068 (Synthetic Human Secretin)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
January 2004
Not Provided

Autism

Both
32 Months to 59 Months
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00036244
RG1068-04
Not Provided
Not Provided
Repligen Corporation
Not Provided
Not Provided
Repligen Corporation
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP